《中国女性乳腺癌筛查指南》解读（精简版）

黄育北; 佟仲生; 陈可欣; 王瑛; 刘佩芳; 顾林; 刘俊田; 于津浦; 宋丰举; 赵文华; 史业辉; 李慧; 肖怀远; 郝希山

doi:10.3969/j.issn.1000-8179.2019.09.581

《中国女性乳腺癌筛查指南》解读（精简版）

doi: 10.3969/j.issn.1000-8179.2019.09.581

黄育北^①,
佟仲生^①,
陈可欣^①,
王瑛^{①, ②},
刘佩芳^①,
顾林^①,
刘俊田^①,
于津浦^①,
宋丰举^①,
赵文华^{①, ②},
史业辉^①,
李慧^①,
肖怀远^①,
郝希山^{①, ②, ,}

①.
天津医科大学肿瘤医院，国家肿瘤临床医学研究中心（天津市300060）
②.
中国抗癌协会

基金项目:

国家科技支撑计划项目 2015BAI12B15

详细信息

通讯作者:
郝希山 xishanhao@sina.com

计量
- 文章访问数: 253
- HTML全文浏览量: 13
- PDF下载量: 64
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-29
- 修回日期: 2019-05-07
- 刊出日期: 2019-05-15

Interpretation of guideline for breast cancer screening in Chinese women

Huang Yubei^①,
Tong Zhongsheng^①,
Chen Kexin^①,
Wang Ying^{①, ②},
Liu Peifang^①,
Gu Lin^①,
Liu Juntian^①,
Yu Jinpu^①,
Song Fengju^①,
Zhao Wenhua^{①, ②},
Shi Yehui^①,
Li Hui^①,
Xiao Huaiyuan^①,
Hao Xishan^{①, ②
, ,}

①.
Tianjin Medical University Cancer Institute and Hospital, National Clinical Reaserch Center for Cancer
②.
China Anti-Cancer Association, Tianjin 300060, China

Funds:

National Key Technology Support Program 2015BAI12B15

More Information

Corresponding author: Xishan Hao; E-mail:xishanhao@sina.com

摘要

摘要: 乳腺癌是中国女性最常见的恶性肿瘤，早期筛查是提高乳腺癌早诊早治最佳途径。中国女性乳腺癌发病高峰年龄与欧美国家乳腺癌发病高峰年龄明显不同，制定适合中国女性特点的群体性乳腺癌筛查指南势在必行。中国抗癌协会与国家肿瘤临床医学研究中心（天津医科大学肿瘤医院）组织专家在分析总结中国女性乳腺癌筛查数据的基础上，参考欧美及东亚等国家的最新乳腺癌筛查指南或共识，分别从筛查起始年龄、筛查方法、筛查时间间隔3个方面，针对中国女性乳腺癌一般风险人群和高危风险人群制定以人群为基础的《中国女性乳腺癌筛查指南》，本文对该指南进行解读以供乳腺癌筛查相关人士参考。
- 乳腺癌 /
- 筛查 /
- 指南
Abstract: Breast cancer is the most common cancer for Chinese women. Early screening is the best way to improve the rates of early diagnosis and early treatment of breast cancer. The peak ages of breast cancer in Chinese women are obviously different from those in the European and American countries. It is imperative to develop a guideline for breast cancer screening that is suitable for Chinese women. Based on the analysis and summary of breast cancer screening data in China, and the latest guidelines and consensus on breast cancer screening in Europe, the United States and East Asia, China Anti-Cancer Association and National Clinical Research Center for Cancer (Tianjin Medical University Cancer Institute and Hospital) has developed a population-based guideline for breast cancer screening in Chinese women. This guideline has provided detailed recommendations on the screening starting age, screening modalities, and screening interval in Chinese women with average risk and high risk of breast cancer, respectively. This article aims to interpret the above guideline, providing references for professionals in breast cancer screening.
- breast cancer /
- screening /
- guideline

HTML全文

参考文献(88)

[1]	Jia M, Zheng R, Zhang S, et al. Female breast cancer incidence and mortality in 2011, China[J]. J Thorac Dis, 2015, 7(7):1221-1226. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgazyj201603006
[2]	Zuo TT, Zheng RS, Zeng HM, et al. Female breast cancer incidence and mortality in China, 2013[J]. Thorac Cancer, 2017, 8(3):214-218. doi: 10.1111/tca.2017.8.issue-3
[3]	陈万青, 郑荣寿, 曾红梅, 等.1989-2008年中国恶性肿瘤发病趋势分析[J].中华肿瘤杂志, 2012, 34(7):517-524. doi: 10.3760/cma.j.issn.0253-3766.2012.07.010
[4]	Zeng H, Zheng R, Zhang S, et al. Incidence and mortality of female breast cancer in China, 2009[J]. Thorac Cancer, 2013, 4(4):400-404. doi: 10.1111/tca.2013.4.issue-4
[5]	Zeng H, Zheng R, Zhang S, et al. Female breast cancer statistics of 2010 in China: estimates based on data from 145 population-based cancer registries[J]. J Thorac Dis, 2014, 6(5):466-470. http://cn.bing.com/academic/profile?id=5c555483dc14014b0b9aced03848fa24&encoded=0&v=paper_preview&mkt=zh-cn
[6]	Chen W, Zheng R, Zuo T, et al. National cancer incidence and mortality in China, 2012[J]. Chin J Cancer Res, 2016, 28(1):1-11. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgazyj201601001
[7]	李贺, 郑荣寿, 张思维, 等.2014年中国女性乳腺癌发病与死亡分析[J].中华肿瘤杂志, 2018, 40(3):166-171. doi: 10.3760/cma.j.issn.0253-3766.2018.03.002
[8]	孙可欣, 郑荣寿, 顾秀瑛, 等.2000-2014年中国肿瘤登记地区女性乳腺癌发病趋势及年龄变化情况分析[J].中华预防医学杂志, 2018, 52 (6):567-572. doi: 10.3760/cma.j.issn.0253-9624.2018.06.003
[9]	Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015, 136(8):1921-1930. http://cn.bing.com/academic/profile?id=484e070786366d08b99f8be681bdd397&encoded=0&v=paper_preview&mkt=zh-cn
[10]	Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016[J]. CA Cancer J Clin, 2016, 66(4):271-289. doi: 10.3322/caac.v66.4
[11]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. doi: 10.3322/caac.21262
[12]	Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-386. doi: 10.1002/ijc.29210
[13]	Huang Y, Dai H, Song F, et al. Preliminary effectiveness of breast cancer screening among 1.22 million Chinese females and different cancer patterns between urban and rural women[J]. Sci Rep, 2016, 6:39459. doi: 10.1038/srep39459
[14]	Shapiro S. Periodic screening for breast cancer: the HIP randomized controlled trial. Health insurance plan[J]. J Natl Cancer Inst Monogr, 1997, 22:27-30. http://cn.bing.com/academic/profile?id=532adc0e7ec2c6599f5f5cfca322789c&encoded=0&v=paper_preview&mkt=zh-cn
[15]	Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and stage distribution by age for the health insurance plan clinical trial[J]. J Natl Cancer Inst, 1988, 80(14):1125-1132. doi: 10.1093/jnci/80.14.1125
[16]	Habbema JD, van Oortmarssen GJ, van Putten DJ, et al. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the health insurance plan of greater New York study[J]. J Natl Cancer Inst, 1986, 77(2):317-320. http://cn.bing.com/academic/profile?id=8bbcabb28cb78f7a36b8b99701b213af&encoded=0&v=paper_preview&mkt=zh-cn
[17]	Shapiro S, Venet W, Strax P, et al. Ten- to fourteen-year effect of screening on breast cancer mortality[J]. J Natl Cancer Inst, 1982, 69(2): 349-355. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=HighWire000005668366
[18]	Miller AB, Wall C, Baines CJ, et al. Twenty-five year follow-up for breast cancer incidence and mortality of the Canadian national breast screening study: randomised screening trial[J]. BMJ, 2014, 348:g366. doi: 10.1136/bmj.g366
[19]	Miller AB, To T, Baines CJ, et al. The Canadian national breast screening study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years[J]. Ann Intern Med, 2002, 137(5 Part 1):305-312. http://cn.bing.com/academic/profile?id=98c37eeca41f206b9fdab574ac01aa5c&encoded=0&v=paper_preview&mkt=zh-cn
[20]	Miller AB, To T, Baines CJ, et al. Canadian national breast screening study-2: 13-year results of a randomized trial in women aged 50-59 years[J]. J Natl Cancer Inst, 2000, 92(18):1490-1499. doi: 10.1093/jnci/92.18.1490
[21]	Miller AB, Baines CJ, To T, et al. Canadian national breast screening study: 1. Breast cancer detection and death rates among women aged 40 to 49 years[J]. CMAJ, 1992, 147(10):1459-1476. http://cn.bing.com/academic/profile?id=baa9059f6038a5338c904e55545d46ff&encoded=0&v=paper_preview&mkt=zh-cn
[22]	Miller AB, Baines CJ, To T, et al. Canadian national breast screening study: 2. Breast cancer detection and death rates among women aged 50 to 59 years[J]. CMAJ, 1992, 147(10):1477-1488. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1336544/
[23]	Moss SM, Wale C, Smith R, et al. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9):1123-1132. doi: 10.1016/S1470-2045(15)00128-X
[24]	Johns LE, Moss SM. False-positive results in the randomized controlled trial of mammographic screening from age 40 (" Age" trial)[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(11):2758-2764. doi: 10.1158/1055-9965.EPI-10-0623
[25]	Moss SM, Cuckle H, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial[J]. Lancet, 2006, 368(9552):2053-2060. doi: 10.1016/S0140-6736(06)69834-6
[26]	Frisell J, Lidbrink E, Hellströ m L, et al. Follow-up after 11 years-update of mortality results in the Stockholm mammographic screening trial[J]. Breast Cancer Res Treat, 1997, 45(3):263-270. doi: 10.1023/A:1005872617944
[27]	Frisell J, Lidbrink E. The Stockholm mammographic screening trial: risks and benefits in age group 40-49 years[J]. J Natl Cancer Inst Monogr, 1997, 22:49-51. http://cn.bing.com/academic/profile?id=6749aacad102fb1d647c6cc1bf115e81&encoded=0&v=paper_preview&mkt=zh-cn
[28]	Frisell J, Eklund G, Hellstrom L, et al. Randomized study of mammography screening-preliminary report on mortality in the Stockholm trial[J]. Breast Cancer Res Treat, 1991, 18(1):49-56. http://cn.bing.com/academic/profile?id=0f09ba5ca282ae595b91742c2cd47c7b&encoded=0&v=paper_preview&mkt=zh-cn
[29]	Frisell J, Glas U, Hellstrom L, et al. Randomized mammographic screening for breast cancer in Stockholm. Design, first round results and comparisons[J]. Breast Cancer Res Treat, 1986, 8(1):45-54. http://cn.bing.com/academic/profile?id=2416b0c65909a2bc847feb55074f3cc6&encoded=0&v=paper_preview&mkt=zh-cn
[30]	Zackrisson S, Andersson I, Janzon L, et al. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study[J]. BMJ, 2006, 332(7543):689-692. doi: 10.1136/bmj.38764.572569.7C
[31]	Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmö mammographic screening program[J]. J Natl Cancer Inst Monogr, 1997, 22:63-67. https://www.researchgate.net/publication/13576591_Reduced_Breast_Cancer_Mortality_in_Women_Under_Age_50_Updated_Results_From_the_Malmo_Mammographic_Screening_Program
[32]	Ikeda DM, Andersson I, Wattsgaå rd C, et al. Interval carcinomas in the Malmö mammographic screening trial: radiographic appearance and prognostic considerations[J]. AJR Am J Roentgenol, 1992, 159(2):287- 294. doi: 10.2214/ajr.159.2.1632342
[33]	Tabár L, Duffy S. Malmö mammographic screening trial[J]. BMJ, 1989, 298(6665):48-49. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_1410836
[34]	Andersson I, Aspegren K, Janzon L, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial[J]. BMJ, 1988, 297(6654):943-948. doi: 10.1136/bmj.297.6654.943
[35]	Andersson I, Janzon L, Sigfusson BF. Mammographic breast cancer screening-a randomized trial in Malmö, Sweden[J]. Maturitas, 1985, 7(1):21-29. doi: 10.1016/0378-5122(85)90031-3
[36]	Bjurstam N, Bjö rneld L, Warwick J, et al. The Gothenburg breast screening trial[J]. Cancer, 2003, 97(10): 2387-2396. doi: 10.1002/cncr.v97:10
[37]	Miller AB, Baines CJ, To T. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization[J]. Cancer, 1998, 83(1):186-190. doi: 10.1002/(ISSN)1097-0142
[38]	Bjurstam N, Bjorneld L, Duffy SW, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization[J]. Cancer, 1997, 80(11):2091-2099. doi: 10.1002/(ISSN)1097-0142
[39]	Bjurstam N, Bjö rneld L, Duffy SW, et al. The Gothenburg breast cancer screening trial: preliminary results on breast cancer mortality for women aged 39-49[J]. J Natl Cancer Inst Monogr, 1997, 22:53-55. http://cn.bing.com/academic/profile?id=5581b4d7fef9495105ad1a714ed38956&encoded=0&v=paper_preview&mkt=zh-cn
[40]	Tabar L, Chen TH, Hsu CY, et al. Evaluation issues in the Swedish twocounty trial of breast cancer screening: an historical review[J]. J Med Screen, 2017, 24(1):27-33. http://cn.bing.com/academic/profile?id=80aa332f66b3bce76680954481ca0d23&encoded=0&v=paper_preview&mkt=zh-cn
[41]	Yen AM, Duffy SW, Chen TH, et al. Long-term incidence of breast cancer by trial arm in one county of the Swedish two-county trial of mammographic screening[J]. Cancer, 2012, 118(23):5728-5732. doi: 10.1002/cncr.v118.23
[42]	Tabar L, Vitak B, Chen TH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades [J]. Radiology, 2011, 260(3):658-663. doi: 10.1148/radiol.11110469
[43]	Duffy SW, Tabar L, Vitak B, et al. The Swedish two- county trial of mammographic screening: cluster randomisation and end point evaluation[J]. Ann Oncol, 2003, 14(8):1196-1198. doi: 10.1093/annonc/mdg322
[44]	Nyströ m L, Andersson I, Bjurstam N, et al. Long- term effects of mammography screening: updated overview of the Swedish randomised trials[J]. Lancet, 2002, 359(9310):909-919. doi: 10.1016/S0140-6736(02)08020-0
[45]	Tabar L, Fagerberg G, Chen HH, et al. Efficacy of breast cancer screening by age. New results from the Swedish two-county trial[J]. Cancer, 1995, 75(10):2507-2517. doi: 10.1002/1097-0142%2819950515%2975%3A10%3C2507%3A%3AAID-CNCR2820751017%3E3.0.CO%3B2-H#references-section
[46]	Wang Q, Li J, Zheng S, et al. Breast cancer stage at diagnosis and areabased socioeconomic status: a multicenter 10- year retrospective clinical epidemiological study in China[J]. BMC Cancer, 2012, 12(1):122. doi: 10.1186/1471-2407-12-122
[47]	Zheng S, Bai JQ, Li J, et al. The pathologic characteristics of breast cancer in China and its shift during 1999- 2008: a national- wide multicenter cross-sectional image over 10 years[J]. Int J Cancer, 2012, 131(11):2622-2631. doi: 10.1002/ijc.v131.11
[48]	李卫芹, 李蓉, 刘佩芳, 等.中国乳腺癌筛查模式探讨[J].中华流行病学杂志, 2016, 37(7):1039-1043. doi: 10.3760/cma.j.issn.0254-6450.2016.07.026
[49]	Corsetti V, Houssami N, Ghirardi M, et al. Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: interval breast cancers at 1-year follow-up[J]. Eur J Cancer, 2011, 47(7):1021-1026. doi: 10.1016/j.ejca.2010.12.002
[50]	Tagliafico AS, Calabrese M, Mariscotti G, et al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial[J]. J Clin Oncol, 2016, 34(16)1882-1888. doi: 10.1200/JCO.2015.63.4147
[51]	Weigert J, Steenbergen S. The connecticut experiments second year: ultrasound in the screening of women with dense breasts[J]. Breast J, 2015, 21(2):175-180. doi: 10.1111/tbj.12386
[52]	Moon HJ, Jung I, Park SJ, et al. Comparison of cancer yields and diagnostic performance of screening mammography vs. supplemental screening ultrasound in 4 394 women with average risk for breast cancer[J]. Ultraschall Med, 2015, 36(3):255-263. https://yonsei.pure.elsevier.com/en/publications/comparison-of-cancer-yields-and-diagnostic-performance-of-screeni
[53]	Parris T, Wakefield D, Frimmer H. Real world performance of screening breast ultrasound following enactment of Connecticut Bill 458[J]. Breast J, 2013, 19(1):64-70. doi: 10.1111/tbj.12053
[54]	Girardi V, Tonegutti M, Ciatto S, et al. Breast ultrasound in 22, 131 asymptomatic women with negative mammography[J]. Breast, 2013, 22(5):806-809. doi: 10.1016/j.breast.2013.02.010
[55]	Leong LC, Gogna A, Pant R, et al. Supplementary breast ultrasound screening in Asian women with negative but dense mammograms-a pilot study[J]. Ann Acad Med Singapore, 2012, 41(10):432-439. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=af48acca113a8b8949be9acbf8cae175
[56]	Youk JH, Kim EK, Kim MJ, et al. Performance of hand-held whole-breast ultrasound based on BI- RADS in women with mammographically negative dense breast[J]. Eur Radiol, 2011, 21(4):667-675. doi: 10.1007/s00330-010-1955-8
[57]	Brancato B, Bonardi R, Catarzi S, et al. Negligible advantages and excess costs of routine addition of breast ultrasonography to mammography in dense breasts[J]. Tumori, 2007, 93(6):562-566. doi: 10.1177/030089160709300608
[58]	Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan strategic anti-cancer randomized trial (J-START): a randomised controlled trial[J]. Lancet, 2016, 387(10016):341-348. doi: 10.1016/S0140-6736(15)00774-6
[59]	Brem RF, Tabar L, Duffy SW, et al. Assessing improvement in detection of breast cancer with three- dimensional automated breast US in women with dense breast tissue: the SomoInsight study[J]. Radiology, 2015, 274(3):663-673. doi: 10.1148/radiol.14132832
[60]	Berg WA, Bandos AI, Mendelson EB, et al. Ultrasound as the primary screening test for breast cancer: analysis from ACRIN 6 666[J]. J Natl Cancer Inst, 2015, 108(4):pii367. http://cn.bing.com/academic/profile?id=522bf78b564ea85d0c48a2a0ba88de37&encoded=0&v=paper_preview&mkt=zh-cn
[61]	Kelly KM, Dean J, Comulada WS, et al. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts[J]. Eur Radiol, 2010, 20(3):734-742. doi: 10.1007/s00330-009-1588-y
[62]	Wilczek B, Wilczek HE, Rasouliyan L, et al. Adding 3D automated breast ultrasound to mammography screening in women with heterogeneously and extremely dense breasts: report from a hospital-based, high-volume, single-center breast cancer screening program[J]. Eur J Radiol, 2016, 85(9):1554-1563. doi: 10.1016/j.ejrad.2016.06.004
[63]	Venturini E, Losio C, Panizza P, et al. Tailored breast cancer screening program with microdose mammography, US, and MR imaging: shortterm results of a pilot study in 40-49-year-old women[J]. Radiology, 2013, 268(2):347-355. doi: 10.1148/radiol.13122278
[64]	Giuliano V, Giuliano C. Improved breast cancer detection in asymptomatic women using 3D-automated breast ultrasound in mammographically dense breasts[J]. Clin Imaging, 2013, 37(3):480-486. doi: 10.1016/j.clinimag.2012.09.018
[65]	Dong H, Huang Y, Song F, et al. Improved performance of adjunctive ultrasonography after mammography screening for breast cancer among Chinese females[J]. Clin Breast Cancer, 2018, 18(3): e353-e361. doi: 10.1016/j.clbc.2017.07.014
[66]	Shen S, Zhou Y, Xu Y, et al. A multi-centre randomised trial comparing ultrasound vs. mammography for screening breast cancer in high-risk Chinese women[J]. Br J Cancer, 2015, 112(6):998-1004. doi: 10.1038/bjc.2015.33
[67]	Tozaki M, Kuroki Y, Kikuchi M, et al. The Japanese breast cancer society clinical practice guidelines for screening and imaging diagnosis of breast cancer, 2015 edition[J]. Breast Cancer, 2016, 23(3):357-366. doi: 10.1007/s12282-016-0674-7
[68]	中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017版)[J].中国癌症杂志, 2017, 27(9):695-760. http://www.cnki.com.cn/Article/CJFDTotal-ZGAZ200705015.htm
[69]	Sankaranarayanan R, Ramadas K, Thara S, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India[J]. J Natl Cancer Inst, 2011, 103(19):1476-1480. doi: 10.1093/jnci/djr304
[70]	Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast- cancer screening (STORM): a prospective comparison study[J]. Lancet Oncol, 2013, 14(7):583-589. doi: 10.1016/S1470-2045(13)70134-7
[71]	Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk[J]. JAMA, 2012, 307(13):1394-1404. doi: 10.1001/jama.2012.388
[72]	Kuhl CK, Schrading S, Strobel K, et al. Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI[J]. J Clin Oncol, 2014, 32(22):2304-2310. doi: 10.1200/JCO.2013.52.5386
[73]	Kriege M, Brekelmans CT, Obdeijn IM, et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer[J]. Breast Cancer Res Treat, 2006, 100(1):109-119. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=89abb88c8d9d2ce6d8de635ad8577562
[74]	Li JY, Jing R, Wei H, et al. Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer [J]. Int J Cancer, 2019, 144(2):281-289. doi: 10.1002/ijc.v144.2
[75]	Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5 931 Chinese women with breast cancer[J]. Breast Cancer Res Treat, 2016, 158(3):455-462. doi: 10.1007/s10549-016-3902-0
[76]	Lang GT, Shi JX, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2, 991 patients and 1, 043 controls by next-generation sequencing[J]. Int J Cancer, 2017, 141(1):129-142. doi: 10.1002/ijc.v141.1
[77]	Yao L, Sun J, Zhang J, et al. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations[J]. Breast Cancer Res Treat, 2016, 156(3): 441-445. doi: 10.1007/s10549-016-3766-3
[78]	BRCA数据解读中国专家共识编写组.BRCA数据解读中国专家共识[J].中华病理学杂志, 2017, 46(5):293-297. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhblx201705002
[79]	Cuzick J, Forbes J, Edwards R, et al. First results from the international breast cancer intervention study (IBIS-I): a randomised prevention trial [J]. Lancet, 2002, 360(9336):817-824. doi: 10.1016/S0140-6736(02)09962-2
[80]	Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study[J]. J Natl Cancer Inst, 1998, 90(18):1371-1388. doi: 10.1093/jnci/90.18.1371
[81]	Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial[J]. Lancet, 1998, 352(9122):98-101. doi: 10.1016/S0140-6736(98)85012-5
[82]	Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian tamoxifen prevention study[J]. Lancet, 1998, 352(9122):93-97. doi: 10.1016/S0140-6736(98)85011-3
[83]	Goss PE, Ingle JN, Alés-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women[J]. N Engl J Med, 2011, 364(25): 2381-2391. doi: 10.1056/NEJMoa1103507
[84]	Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-Ⅱ): an international, double-blind, randomised placebo-controlled trial[J]. Lancet, 2014, 383 (9922):1041-1048. doi: 10.1016/S0140-6736(13)62292-8
[85]	Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 4. 2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2018, 16(3):310-320. doi: 10.6004/jnccn.2018.0012
[86]	Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers[J]. J Natl Cancer Inst, 2001, 93(21):1633-1637. doi: 10.1093/jnci/93.21.1633
[87]	Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers[J]. J Natl Cancer Inst, 2009, 101(2): 80-87. doi: 10.1093/jnci/djn442
[88]	Wong IO, Kuntz KM, Cowling BJ, et al. Cost effectiveness of mammography screening for Chinese women[J]. Cancer, 2007, 110(4):885- 895. doi: 10.1002/(ISSN)1097-0142